A core outcome set for localised prostate cancer effectiveness trials.

Citation data:

BJU international, ISSN: 1464-410X, Vol: 120, Issue: 5B, Page: E64-E79

Publication Year:
2017
Usage 45
Abstract Views 43
Link-outs 2
Captures 10
Readers 10
Mentions 1
News Mentions 1
Social Media 1
Tweets 1
Citations 3
Citation Indexes 3
PMID:
28346770
DOI:
10.1111/bju.13854
Author(s):
Steven MacLennan, James N'Dow, Sara MacLennan, Thomas Lam, Paula R. Williamson, Hanneke Bekema, Marion Campbell, Craig Ramsay, Luke Vale, Philipp Dahm, Nicolas Mottet, Paul Abel, Hashim U. Ahmed, Gary Akehurst, Robert Almquist, Karl Beck, David Budd, Steven Canfield, James Catto, Philip Cornford, William Cross, Alexander Ewen, Judith Grant, Rakesh Heer, David Hurst, Rob Jones, Roger Kockelbergh, Andrew Mackie, Graham MacDonald, Alan McNeill, Malcolm Mason, Sam McClinton, Duncan McLaren, Hugh Mostafid, Ian Pearce, Linda Pennet, Justine Royle, Hans Schreuder, Grant D. Stewart, Henk van der Poel, Kevin Wardlaw, Thomas Wiegel Show More Hide
Publisher(s):
Wiley-Blackwell
Tags:
Medicine
Most Recent Tweet View All Tweets
Most Recent News Mention
article description
To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which offers the optimal therapeutic ratio; which is confounded by inconsistencies in the selection, definition, measurement and reporting of outcomes in clinical trials.

This article has 0 Wikipedia mention.